CJEU adviser to give opinion on SPC term

An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate (SPC) begins once it is authorised or when the applicant has been notified about it.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

More features

Siemens ordered to recall mammography device across European countries

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Ex-Kirkland patent litigator jumps to rival firm

CJEU adviser to give opinion on SPC term

More on this story

Editor's picks

Editor's picks

More features